References
- Rivera ME, Frank I, Viers BR, et al. Holmium laser enucleation of the prostate and perioperative diagnosis of prostate cancer: an outcomes analysis. J Endourol. 2014;28:699–703.
- Kim M, Song SH, Ku JH, et al. Prostate cancer detected after Holmium laser enucleation of prostate (HoLEP): significance of transrectal ultrasonography. Int Urol Nephrol. 2014;46:2079–2085.
- Nunez R, Hurd KJ, Noble BN, et al. Incidental prostate cancer revisited: early outcomes after holmium laser enucleation of the prostate. Int J Urol. 2011;18:543–547.
- Otsubo S, Yokomizo A, Mochida O, et al. Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate. World J Urol. 2015;33:329–333.
- Elkoushy MA, Elshal AM, Elhilali MM. Incidental prostate cancer diagnosis during holmium laser enucleation: assessment of predictors, survival, and disease progression. Urology. 2015;86:552–557.
- Bhojani N, Boris RS, Monn MF, et al. Coexisting prostate cancer found at the time of holmium laser enucleation of the prostate for benign prostatic hyperplasia: predicting its presence and grade in analyzed tissue. J Endourol. 2015;29:41–46.
- Hurle R, Vavassori I, Piccinelli A, et al. Holmium laser enucleation of the prostate combined with mechanical morcellation in 155 patients with benign prostatic hyperplasia. Urology. 2002;60:449–453.
- Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–1685.
- Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006;15:1977–1983.
- Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–841.
- Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166:1871–1877.
- Ohwaki K, Endo F, Muraishi O, et al. Relationship between changes in haemoglobin A1C and prostate-specific antigen in healthy men. Eur J Cancer. 2011;47:262–266.
- Bassett JK, Severi G, Baglietto L, et al. Weight change and prostate cancer incidence and mortality. Int J Cancer. 2012;131:1711–1719.
- Stocks T, Hergens MP, Englund A, et al. Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. Int J Cancer. 2010;127:1660–1668.
- Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:63–69.
- Pischon T, Boeing H, Weikert S, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008;17:3252–261.
- Leitzmann MF, Ahn J, Albanes D, et al. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008;19:1267–1276.
- Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5–15.
- Yassin DJ, Doros G, Hammerer PG, et al. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med. 2014;11:1567–1576.
- Grosman H, Rosales M, Fabre B, et al. Association between testosterone levels and the metabolic syndrome in adult men. Aging Male. 2014;17:161–165.
- Grosman H, Fabre B, Lopez M, et al. Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease. Aging Male. 2016;19:40–45.
- Khera M, Crawford D, Morales A, et al. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014;65:115–123.